Brought to you by 
PTC Therapeutics goes public on second try with $134mm IPO
27 Feb 2023
Executive Summary
Just over three months after completing a $60mm Series G financing, PTC Therapeutics Inc. (focused on orphan and ultra-orphan diseases) has netted $134mm through its initial public offering of 9.6mm common shares (including the overallotment) at $15. Just days ago the company said it intended to sell 6.9mm shares between $13-16. This was PTC's second try after withdrawing an S-1 filing in 2007 because it already had sufficient funding through grants and licensing deals.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PTC Therapeutics goes public on second try with $134mm IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice